This article is more than 5 years old. Information may no longer be current.

XOMA launches gevokizumab study for treatment of Behçet’s disease uveitis

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

XOMA announced the launch of a U.S. clinical trial to investigate the safety and efficacy of gevokizumab for the treatment of patients with Behçet’s disease uveitis, according to a press release issued by the company.

The EYEGUARD-US trial will comprise up to 28 patients administered the monoclonal antibody, gevokizumab, in an open-label design. Patients who respond to gevokizumab by day 28 will be randomly assigned in a 1:1, double-masked fashion to either gevokizumab 60 mg or placebo, administered subcutaneously once monthly, according to the press release. The study’s primary endpoint is the time to first ocular exacerbation following randomization.

Behçet’s disease is considered an orphan disease that causes chronic vasculitis. Without treatment, the disease can lead to retinal detachment, vitreous hemorrhage, glaucoma and eventual blindness.

For more information:

ClinicalTrials.gov Identifier: NCT01965145.